Korean J Hematol.  2011 Dec;46(4):239-243. 10.5045/kjh.2011.46.4.239.

Indeterminate lupus anticoagulant results: Prevalence and clinical significance

• Alkayed K
• Kottke-Marchant K

• KMID: 2251984
• DOI: http://doi.org/10.5045/kjh.2011.46.4.239

Abstract

BACKGROUND
Reports of indeterminate lupus anticoagulant (LAC) results are common; however, no published data on their prevalence or clinical significance are available. We investigated the prevalence and clinical characteristics of patients with indeterminate LAC.
METHODS
We retrospectively reviewed the clinical and serologic characteristics of 256 unselected patients with LAC results.
RESULTS
Indeterminate results were observed in 32.7% of LAC profiles that were least frequent (25.4%) when activated partial thromboplastin time (aPTT) was normal, most frequent (39.8%) when aPTT was elevated, and were observed in 35% of patients taking warfarin. The final indeterminate LAC cohort included 65 patients with a mean follow-up of 18 months. Malignancy and autoimmune disease were present in 29% and 25% of patients, respectively. The most common thrombotic events were deep vein thrombosis (DVT) (28%), cerebral ischemic stroke (14%) and pulmonary embolism (14%). Patients with indeterminate results were more likely to be men, older, and with a history of DVT, superficial thrombosis, or myocardial infarction than patients with negative tests (N=106). Concurrent warfarin therapy was more prevalent in the indeterminate group, but was not statistically significant. In the multivariate analysis, none of the variables showed statistical significance. During follow-up, 10 of 16 patients with indeterminate results showed change in classification upon retesting.
CONCLUSION
Patients with indeterminate LAC results were common, and their clinical characteristics differed from those with negative results. There is a need for a prospective study of the clinical history of patients with indeterminate LAC results.

Keyword

Antiphospholipid antibodies; Antiphospholipid syndrome; Indeterminate lupus anticoagulant

MeSH Terms

Antibodies, Antiphospholipid
Antiphospholipid Syndrome
Autoimmune Diseases
Cohort Studies
Follow-Up Studies
Humans
Lupus Coagulation Inhibitor
Male
Multivariate Analysis
Myocardial Infarction
Partial Thromboplastin Time
Prevalence
Pulmonary Embolism
Retrospective Studies
Stroke
Thrombosis
Venous Thrombosis
Warfarin
Antibodies, Antiphospholipid
Lupus Coagulation Inhibitor
Warfarin

Reference

1. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952; 31:621–622.

2. Feinstein DI, Rappaport SI. Acquired inhibitors of blood coagulation. Prog Hemost Thromb. 1972; 1:75–95. PMID: 4569725.

3. Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med. 1980; 92:156–159. PMID: 7352719.

4. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003; 101:1827–1832. PMID: 12393574.

5. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995; 74:1185–1190. PMID: 8560433.

6. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009; 7:1737–1740. PMID: 19624461.

7. Asherson RA. Antiphospholipid antibodies, malignancies and paraproteinemias. J Autoimmun. 2000; 15:117–122. PMID: 10968896.

8. Hughes GR, Khamashta MA. The antiphospholipid syndrome. J R Coll Physicians Lond. 1994; 28:301–304. PMID: 7965966.

9. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol. 2000; 109:704–715. PMID: 10929019.

10. Tripodi A, Chantarangkul V, Clerici M, Mannucci PM. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost. 2002; 88:583–586. PMID: 12362227.

11. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4:295–306. PMID: 16420554.

12. Olteanu H, Downes KA, Patel J, Praprotnik D, Sarode R. Warfarin does not interfere with lupus anticoagulant detection by dilute Russell's viper venom time. Clin Lab. 2009; 55:138–142. PMID: 19462936.

13. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000; 15:145–151. PMID: 10968901.

14. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005; 3:1993–1997. PMID: 16102105.

15. Sidelmann JJ, Sjøland JA, Gram J, et al. Lupus anticoagulant is significantly associated with inflammatory reactions inpatients with suspected deep vein thrombosis. Scand J Clin Lab Invest. 2007; 67:270–279. PMID: 17454841.

16. Leon L, Giannoukas AD, Dodd D, Chan P, Labropoulos N. Clinical significance of Superficial Vein Thrombosis. Eur J Vasc Endovasc Surg. 2005; 29:10–17. PMID: 15570265.

17. Rees JD, Lanca S, Marques PV, et al. Prevalence of the antiphospholipid syndrome in primary systemic vasculitis. Ann Rheum Dis. 2006; 65:109–111. PMID: 16344494.

18. Heneghan MA, Cleary B, Murray M, O'Gorman TA, McCarthy CF. Activated protein C resistance, thrombophilia, and inflammatory bowel disease. Dig Dis Sci. 1998; 43:1356–1361. PMID: 9635631.